Dipirona Klonal

Quick links

Choose a section

Quick links to important sections

Advertisements

Dipirona Klonal

Advertisements
Advertisements

Overview of Dipirona Klonal

Property Description
Active ingredient Sodium Metamizole
Forms Tablets, Oral Drops, Injectable Solution
Pharmacological class Non-opioid Analgesic, Antipyretic, Pyrazolone Derivative
General Purpose Relief from strong pain, fever reduction, spasm relief
Origin Synthetic

Dipirona Klonal: Identity, Classification, and Composition

Dipirona Klonal is a pharmaceutical preparation distinguished by its core active ingredient, Sodium Metamizole. It is officially classified as a potent non-opioid analgesic and antipyretic, functioning as a strong agent for symptomatic relief.

The active substance, Sodium Metamizole (also recognized as Dipyrone or Sulpyrine), is a chemically synthetic compound belonging to the pyrazolone derivative chemical family. This substance is clinically recognized for its efficacy in reducing elevated body temperature and managing fever. Its distinct structure positions it as an effective option where powerful pain relief and fever control are required, differentiating it from agents in the Non-steroidal Anti-inflammatory Drug (NSAID) class. Dipirona Klonal is a prescription-only medicine (Rx).

Available Forms and General Therapeutic Purpose

Sodium Metamizole is manufactured in several fundamental pharmaceutical preparations, including tablets, oral drops, and a sterile solution for injection.

The availability across these dosage forms permits flexibility in the routes of administration, such as oral, intravenous, or intramuscular, particularly when immediate or sustained relief is necessary. The general therapeutic purpose is defined by its strong analgesia and efficient antipyresis, which are combined with a pharmacologically unique spasmolytic property. This triple action allows the medication to relax certain smooth muscles, making the preparation valuable for managing discomfort where both severe pain and associated internal cramping are present.

Advertisements

What side effects are possible with Dipirona Klonal?

Possible Side Effects and Safety Information

The safety profile of Dipirona Klonal (Sodium Metamizole) is formally documented in official regulatory sources, which classify potential adverse reactions based on their frequency and the body system affected. All documented information is based on the data reported to government health authorities.

Serious Adverse Reactions and Blood System Effects

The most serious potential effect documented in regulatory warnings is agranulocytosis, a rare but potentially life-threatening reaction affecting the blood and lymphatic system. This effect is noted to be independent of the administered dose and may occur at any time during treatment. Other officially listed severe blood disorders include leucopenia, thrombocytopenia, and pancytopenia. Severe systemic reactions, such as anaphylactic shock and severe skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are classified as very rare.

System-Specific Effects and Frequency

Adverse effects are categorized by the physiological systems they impact, as noted in the official prescribing information:

  • Uncommon reactions include hypotension, which is more frequently observed after injection and can be dose-dependent.
  • Rare effects involve various hypersensitivity reactions (anaphylactoid reactions) and minor skin reactions.
  • Renal and Urinary Disorders such as interstitial nephritis and acute renal failure are documented, especially in patients with volume depletion or pre-existing renal compromise.
  • Hepatobiliary Disorders, including drug-induced liver injury (DILI), have been reported with a frequency not known.

Safety Considerations and Limitations

Official documents include safety notes for certain populations. Specific caution is advised for older adults and individuals with impaired hepatic or renal function due to potential changes in drug clearance. Use is generally restricted in patients with pre-existing blood disorders (e.g., bone marrow suppression) or known hypersensitivity to pyrazolones.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents and prescribing information for the active ingredient, Sodium Metamizole.

Overdose with Sodium Metamizole may lead to severe and life-threatening outcomes, which require immediate medical intervention.


Documented Overdose Manifestations

System Official Manifestations
Gastrointestinal Nausea, vomiting, and abdominal pain.
Central Nervous System Somnolence, vertigo, restlessness, delirium, or convulsions.
Severe Outcomes Circulatory shock (severe hypotension), acute kidney failure, and acute liver damage.

Emergency Response and Management

When to Seek Immediate Help: Patients must seek immediate medical attention or contact emergency services in the event of any suspected overdose or upon the onset of symptoms, especially signs of shock or convulsions.

Antidote and Treatment: No specific antidote is known for Sodium Metamizole intoxication. Treatment is primarily symptomatic and supportive, aiming to maintain vital functions. Procedures to limit drug absorption, such as gastric lavage or administering activated charcoal, are noted as initial measures if ingestion occurred recently. In severe cases, haemodialysis may be necessary to accelerate the elimination of metabolites.

Population Note: Due to potentially prolonged elimination, patients with known renal or hepatic impairment may require special consideration to avoid multiple high doses.

Advertisements

Therapeutic Uses of Dipirona Klonal

Metamizole-containing medicines are indicated for treating moderate to severe pain and fever. Dipirona Klonal is commonly used to help with symptomatic relief for symptoms related to physical discomfort that may interfere with daily functioning. The medication is relevant in contexts involving symptoms associated with acute or episodic changes, such as post-operative discomfort or certain headache manifestations, and is applied when additional management of discomfort is required.

The core therapeutic domains include support for managing severe pain, assistance with the reduction of high-grade fever, and easing of discomfort from internal muscle spasms (colic).

The medication is applied in addressing symptom clusters related to heightened physiological activity, especially sharp, cramping discomfort, which is relevant for managing symptoms during episodes of colic pain. By addressing this symptom cluster, it contributes to improved comfort during symptomatic periods.

“The support provided may assist with maintaining functional stability during symptomatic phases.”

This medication is commonly used to help with symptoms related to systemic imbalance, specifically managing high-grade fever that may become more disruptive during flare-ups. The medication helps to contribute to improved comfort by easing symptoms related to systemic imbalance.

Quick Fact: Relief for Severe Pain, Colic Discomfort, and High Fever

Regulatory References

  1. European Medicines Agency referral page
Advertisements

Eligibility and Restrictions for Use

Eligibility to Use Dipirona Klonal (Sodium Metamizole)

The eligibility for Dipirona Klonal is strictly regulated by official documentation and defined by patient health history and specific physiological conditions.

Contraindicated Populations (Must Not Use)

Contraindication Category Eligibility Status
History of Metamizole-Induced Agranulocytosis Contraindicated
Diseases of the Haematopoietic System Contraindicated
Acute Intermittent Hepatic Porphyria Contraindicated
Third Trimester of Pregnancy Contraindicated

Restricted and Conditional Use

Use is not recommended or requires special caution for several populations. Individuals with severe renal (kidney) failure or hepatic (liver) failure must use the medicine under restricted circumstances due to the risk of metabolite accumulation. Use during lactation (breastfeeding) is generally not recommended, and regulatory guidelines advise avoiding breastfeeding for 48 hours following a single dose. Fixed-dose oral forms are not recommended for children under 15 years; however, weight-adjusted dosing is established for younger children and adolescents using other pharmaceutical preparations. Older adults and those with compromised circulation require cautious administration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dipirona Klonal (Sodium Metamizole) enters into several officially documented interaction patterns that influence the clearance and activity of co-administered substances. The primary mechanism is classified as a pharmacokinetic interaction through enzyme induction.

Metamizole acts as a moderate to strong inducer of Cytochrome P450 enzymes CYP3A4, CYP2B6, and CYP2C19. This induction effect results in the reduction of plasma concentrations for medicines that are substrates of these enzymes, including the immunosuppressant Ciclosporin and the sedative Midazolam. A reduced concentration of these medicines can potentially decrease their effectiveness.

Pharmacodynamic interactions are also documented. Co-administration with Methotrexate carries an officially stated additive risk of severe haematologic toxicity, making this combination a high-risk regulatory constraint. Furthermore, Metamizole inhibits the antiplatelet effect of Acetylsalicylic acid (Aspirin) when it is used for cardiovascular protection. To mitigate this effect, official instructions mandate that Acetylsalicylic acid must be administered at least 30 minutes prior to Metamizole.

Use is also restricted with Alcohol (Ethanol), as official regulatory documents indicate this combination carries an increased risk of stomach problems. Another documented pharmacodynamic risk is the potential for additive severe hypothermia when co-administered with Chlorpromazine.

Advertisements

Mechanism of Action

How Dipirona Klonal Works: Mechanism of Action

Dipirona Klonal (Sodium Metamizole) exerts its effects through its active metabolites, primarily by engaging several distinct and complementary mechanisms, resulting in central nociceptive signal suppression, thermoregulatory adjustment, and smooth muscle relaxation.


Central Suppression of Nociceptive Signaling

The drug's mechanism for pain signal modulation is mediated chiefly within the Central Nervous System (CNS). Its metabolites selectively inhibit the COX-3 enzyme, which is key to generating Prostaglandin E2 ( PGE2) in the spinal cord and brain. Simultaneously, the drug modulates descending inhibitory pathways by acting as an agonist on the Cannabinoid receptor type 1 (, CB1 ) and the opioidergic system, effectively suppressing the transmission of nociceptive signals to higher centers in the CNS.


Hypothalamic Thermoregulatory Adjustment

The mechanism for thermoregulatory adjustment is achieved through a direct central effect on the hypothalamic thermoregulatory center. By inhibiting PGE2 synthesis in this region, the drug halts the process that elevates the body's temperature set-point during febrile states. This molecular action triggers the resetting of the set-point to a normal physiological level, initiating heat dissipation mechanisms following the set-point adjustment.


Visceral Smooth Muscle Relaxation

The mechanism for smooth muscle relaxation involves modulation of ionic control within smooth muscle cells of internal organs. The active compounds interfere with the release of intracellular calcium ions (, Ca^2+ ) and activate ATP-sensitive potassium channels (, K ATP ) . This combined mechanistic cascade leads to the hyperpolarization and relaxation of the muscle cell, which reduces sustained tissue tension in visceral smooth muscle.

Advertisements

Dosage and Administration Information

How to Use Dipirona Klonal

The usage of Dipirona Klonal (Sodium Metamizole) is strictly governed by precise dosing ranges, frequency, and administration routes detailed in official prescribing information. The medication is intended for short-term use only, typically for acute symptomatic episodes.

Administration Routes and Dosing

Dipirona Klonal is administered via multiple official routes, including oral (tablets or drops), intravenous (IV), intramuscular (IM), and, in some regions, rectal administration.

The treatment should consistently start at the lowest dose that can manage the symptom. For adults (ge 15 years or ge 53 kg), the standard single oral dose is 500 mg to 1,000 mg. This dose can be taken up to four times daily at intervals of 6 to 8 hours, corresponding to a maximum daily dose of 4,000 mg. The single parenteral (IV/IM) dose is also 500 mg to 1,000 mg, with a standard maximum daily dose of 4,000 mg, though up to 5,000 mg may be permitted in certain high-necessity scenarios.

Procedural and Population Rules

Procedural Rule Official Instruction
Pediatric Dosing Single dose calculation is based on body weight, typically 8–16 mg/kg body weight.
IV Administration Must be administered very slowly to comply with proper clinical practice.
Impaired Function A reduced dose should be used for older adults or patients with known kidney or liver impairment, as the elimination of metabolites can be prolonged.

A clear effect is anticipated 30 to 60 minutes after oral intake, or within 30 minutes following parenteral administration.

Advertisements

Recent Clinical Evidence

Dipirona Klonal (Metamizole): Recent Clinical Evidence

Dipirona, known internationally as metamizole, is a non-opioid analgesic and antipyretic agent used globally to address moderate to severe pain, fever, and spasm. Its clinical use has a long history, though regulatory status varies significantly across countries due to safety considerations.

Efficacy Profile

Clinical trials and systematic reviews often focus on the drug's role in acute pain management. A single oral dose of 500 mg of dipyrone has been associated with pain relief (at least 50% reduction) in a higher percentage of patients with acute postoperative pain compared to a placebo, with the effect generally observed within four to six hours. Further research suggests its effectiveness in managing various pain types, including postoperative pain, colic, and migraine attacks.

Studies also explore the drug's spasmolytic (smooth muscle relaxing) properties, which are distinct from those of traditional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Research suggests the drug may be effective in pain associated with spasms, such as renal or biliary colic.

Safety and Tolerability

The primary safety concern associated with metamizole use is the risk of agranulocytosis (a severe reduction in white blood cells), which has led to its withdrawal from markets in some countries, including the United States and the United Kingdom. However, data from countries where the drug remains widely used suggest that the estimated incidence of this adverse effect is rare, typically ranging from 1 in 10,000 to 1 in 1,000,000 exposed persons.

Reported adverse events for short-term use are often mild and temporary. Studies have examined its tolerability profile, which may show a lower incidence of common gastrointestinal adverse effects compared to some conventional NSAIDs. Ongoing research continues to evaluate the overall benefit-risk balance, particularly for long-term use and specialized patient populations.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dipirona Klonal (FAQ)

Q: How long do the effects of Dipirona Klonal usually last?

A: According to regulatory summaries, the pain-relieving effects of the active ingredient, metamizole, are generally described as lasting between 4 to 6 hours after administration. The onset of effect is anticipated relatively quickly, but the full duration of its action in the body is within this range.

Q: What is the difference between Dipirona Klonal and common pain relievers like acetaminophen?

A: Official information distinguishes Dipirona Klonal (metamizole) chemically, classifying it as a pyrazolone derivative, which is different from acetaminophen. Metamizole is also noted for having a spasmolytic property—meaning it can relax certain smooth muscles—which is a function not typically shared by acetaminophen and many other common pain relievers.

Q: Does Dipirona Klonal cause drowsiness or affect my ability to drive?

A: Regulatory documents advise caution regarding activities that require focus, such as driving or operating machinery. This warning is due to the potential for adverse effects like hypotension (low blood pressure) or other central nervous system effects. Regulatory warnings indicate that individuals may experience impaired reaction ability.

Q: Does Dipirona Klonal interact with medications for mental health conditions?

A: Regulatory product information notes that metamizole is known to induce, or speed up, the action of certain Cytochrome P450 enzymes in the body. Because many medications used for mental health conditions are broken down by these same enzymes, this mechanism of interaction suggests a potential for reduced concentration and effectiveness.

Q: Is it safe to take Dipirona Klonal if I have a history of stomach ulcers?

A: Official regulatory warnings list gastrointestinal bleeding and ulceration as potential adverse effects. Specific pre-existing conditions, such as a history of stomach ulcers, are generally noted in regulatory documents as circumstances that may require special caution.

Q: What information is available regarding long-term use of Dipirona Klonal?

A: Metamizole is officially intended for short-term use for acute symptoms. Regulatory warnings state that long-term use or use exceeding the maximum recommended duration increases the risk profile, particularly the rare but serious risk of blood disorders like agranulocytosis.

Q: Is Dipirona Klonal used for migraine headaches?

A: Yes, official indications and clinical evidence confirm that metamizole is used for pain of various origins. In some regulatory documents, its use in treating migraine attacks is specifically listed as one of its defined therapeutic purposes.

Q: How does the mechanism of action of Dipirona Klonal differ from aspirin?

A: The mechanism of metamizole is described as acting primarily on the central nervous system (CNS), partly by inhibiting the COX-3 enzyme. This differs from aspirin, which mainly inhibits the peripheral COX-1 and COX-2 enzymes. Furthermore, regulatory documents warn that metamizole may specifically inhibit the antiplatelet effect of low-dose aspirin when taken concurrently.

Q: Why is Dipirona Klonal available over the counter in some countries but not others?

A: The differences in regulatory status across countries are officially linked to variations in the national health authorities' risk assessments. The main point of regulatory debate is the severe, rare adverse event of agranulocytosis, which has led some countries (like the US and UK) to withdraw it, while others maintain it as a prescription or over-the-counter medicine.

Q: Is there a link between Dipirona Klonal and changes in blood pressure?

A: Official regulatory documentation lists hypotension (low blood pressure) as an uncommon adverse reaction associated with the use of metamizole. This effect is more frequently noted following administration by injection and can sometimes be related to the size of the dose.

Q: Can Dipirona Klonal be taken by people with asthma?

A: Official warnings specifically advise that patients with non-allergic asthma or a history of intolerance to analgesics are at a higher risk of developing a serious hypersensitivity reaction to metamizole. Official warnings note that this pre-existing condition is associated with a higher risk profile for hypersensitivity reactions.

Q: If I miss a dose of Dipirona Klonal, what does the general instruction suggest?

A: General instructions found in regulatory leaflets address missed doses by focusing on maintaining the prescribed interval and specifically advise against taking a compensatory double dose. The guidance is intended to prevent excessive or improper use.

Q: Are there any known interactions between Dipirona Klonal and oral contraceptives?

A: Official product documents indicate that metamizole can induce the CYP3A4 enzyme. Since many oral contraceptives are broken down by this same enzyme, there is a theoretical risk that this interaction may potentially lead to a reduction in the effectiveness of the contraceptive medicine.

Q: What are the criteria for stopping Dipirona Klonal according to official documents?

A: Official regulatory warnings describe circumstances that require immediate discontinuation of the medicine, such as the development of signs related to potential blood disorders like agranulocytosis. These signs typically include unexplained high fever, chills, sore throat, or painful inflammation in the mouth.

Q: Does Dipirona Klonal carry a risk of dependence or addiction?

A: Regulatory documents classify the active ingredient as a non-opioid analgesic. It is not listed as a controlled substance in jurisdictions where it is approved, and its mechanism of action is distinctly different from that of opioid drugs which are associated with risks of dependence or addiction.

Q: Does Dipirona Klonal interact with blood sugar medications?

A: Metamizole is a known enzyme inducer, and regulatory documents list that it can potentially affect the plasma concentrations of other medicines. While specific blood sugar medications (antidiabetics) are often not named, their metabolism may be affected by the documented CYP enzyme induction.

Q: What is the general advice for patients who experience dizziness after taking Dipirona Klonal?

A: Official guidance notes that if a person experiences symptoms such as dizziness or low blood pressure (hypotension), they may be advised against engaging in activities like driving or operating machinery, as these effects can impair ability. This is documented in the product safety information.

Q: Can people with G6PD deficiency use Dipirona Klonal?

A: Official regulatory documents typically include Glucose-6-phosphate dehydrogenase (G6PD) deficiency in the list of contraindications or conditions requiring specific caution. This is because using metamizole in patients with this condition may carry a risk of inducing hemolysis (the destruction of red blood cells).

Q: Does Dipirona Klonal affect fertility?

A: Regulatory documents state that studies in animals have not shown harmful effects on fertility. However, the risk to human fertility is not fully known and is generally not specifically addressed in detail within the available clinical data sections.

Q: Can Dipirona Klonal interact with herbal products like St. John's Wort?

A: Official information documents metamizole's ability to induce the CYP3A4 enzyme. Since St. John's Wort is a known strong inducer of the same enzyme, co-administration may lead to complex or excessive changes in the metabolism of other medications.

Q: What is the general expected response if Dipirona Klonal is used for pain relief?

A: The general therapeutic purpose is defined in official documents as providing strong analgesia (pain relief). A clear effect for acute pain is anticipated to begin within 30 to 60 minutes after oral administration.

Advertisements

How should Dipirona Klonal be stored and disposed of?

Storage and Disposal Requirements

Official labeling for Dipirona Klonal (Metamizole Sodium) defines specific mandatory conditions to maintain stability and ensure safety. Storage must occur under controlled environmental conditions, typically requiring the product to be kept below 30 C and protected from light.

Condition Requirement
Temperature Store below 30 C and away from excessive heat.
Protection Protect from light; keep the container tightly closed.
Child Safety Must be stored out of the sight and reach of children.
Stability Any solution diluted for infusion must be administered immediately, and unused portions of single-dose containers must be discarded.

Disposal of unused or expired medicine should follow official guidance. The primary method involves utilizing drug take-back programs. If a program is unavailable, follow the procedure of mixing the product with an undesirable substance, then sealing it for disposal in the household trash, while avoiding release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dipirona Klonal found in:

A-Z Index: